Percheron Therapeutics Ltd
Company Profile
Business description
Percheron Therapeutics Ltd is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the difficult-to-treat cancers. The company's product pipeline comprises the following drug candidates: avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, and HMBD-002, a monoclonal antibody that has shown activity in a wide range of animal models of cancer and has shown evidence of synergy when combined with other immuno-oncology drugs such as Keytruda (pembrolizumab). Its operating segments are ATL1102, which generates maximum income, and HMBD-002.
Contact
35 Collins Street
Level 30, Collins Place
MelbourneVIC3000
AUST: +61 398278999
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
Employees
8
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |